Accelerating drug development timelines – Evolution in trial design approaches in oncology

Three specialists – Dr. Sarah Blagden, Associate Professor of Medical Oncology, University of Oxford; Maria Prendes, Head of Oncology at the Covance Biomarker Solution Center; and Kamal Saini, Senior Medical Director of Oncology at Covance – recently discussed this highly relevant topic in an educational webinar, which is now available …

stairs leading upward

Beyond Product Characterization: Analytical techniques that advance biopharmaceutical development

Evaluating your product beyond standard characterization can provide a comprehensive understanding of a molecule in early phase development. Allan Watkinson, PhD, Director of Biopharmaceutical Development CMC at Covance, recently discussed a few of the assays that can help drug development sponsors gain new insights about their product and making earlier …

tech woman

Decentralized Clinical Trials (DCT) Monthly Blog – November 2020

Welcome to the November 2020 edition of the Covance DCT blog. The current discussions around the clinical trial industry are heavily weighted around Decentralized Trials (DCT) and how COVID19 has been a catalyst. This has heighted the awareness across our industry as we are finding many new technology companies entering this …


What is an Inhalation reprotoxicology study – insights, advice, and secrets

What is Inhalation Reprotoxicology and When is it Relevant? Inhalation reprotoxicology studies are required when a chemical substance or plant protection product (PPP) is suspected of having the potential to cause reproductive or developmental toxicity and there is the possibility that human exposure can occur via the respiratory system.

Immunophenotyping with immunohistochemistry: interspecies considerations impacting the success of your nonclinical studies

Immunohistochemistry (IHC) is a useful tool for immunophenotyping because it enables the visualization of immune system cells in context of their tissue environment. This post examines IHC in relation to other immunophenotyping tools and highlights the challenges of interspecies interpretation of IHC from toxicological pathology during early drug or preclinical …


Key Considerations for Medical Monitoring in CAR T Clinical Trials During the COVID-19 Pandemic and Beyond

The following blog is an adaptation of a conference presentation by Covance in September 2020 that was also re-recorded and available here Background: Medical monitoring supports the correct determination of patient eligibility for CAR T-cell therapy and plays a key role in monitoring quality patient care throughout CAR T clinical …